Products
Gilvetmab Biosimilar Canine Monoclonal Antibody (Canine PD-1) for Research
Cat No.: GMP-Bios-ab-243
Pre-Made Gilvetmab biosimilar, Canine Whole Mab: Anti-PDCD1 (Canine) therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-243-1mg | 1mg | 3090 |
| GMP-Bios-ab-243-10mg | 10mg | |
| GMP-Bios-ab-243-100mg | 100mg | |
| GMP-Bios-ab-243-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Gilvetmab biosimilar, Canine Whole Mab: Anti-PDCD1 (Canine) therapeutic antibody |
| INN Name | Gilvetmab |
| Target | PDCD1 (Canine) |
| Format | Canine Whole mAb |
| Derivation | Caninized |
| Species Reactivity | Canine |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Unknown |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Merck |
| Conditions Approved | na |
| Conditions Active | Canine Cancers |
| Conditions Discontinued | na |
| Development Tech | na |
